de Verneuil Vanina
Known title: EVP and General CounselCIK: 0002036234
Associated companies
Transaction History
| VIR | ▼ Sell | Open Market | 13,700 | $135K | 2/25/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 3,117 | $30K | 2/24/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 4,445 | $33K | 2/23/2026 | View on chart |
| VIR | ▲ Buy | Grant | 55,000 | $0 | 2/22/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 2,385 | $12K | 11/5/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 1,365 | $8K | 11/3/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 7,373 | $67K | 2/26/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 5,140 | $49K | 2/24/2025 | View on chart |
| VIR | ▲ Buy | Grant | 35,000 | $0 | 2/22/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 76 | $625 | 12/2/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 4,397 | $44K | 11/6/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 2,347 | $22K | 11/5/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 1,403 | $10K | 11/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates
Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.